| 2025-07-31 |
复牌提示：
2025-07-30 19:50:00 停牌，复牌日期 2025-08-01 00:00:01
|
| 2025-07-31 |
详情>>
内部人交易：
Greene Barry E等共交易9笔
|
| 2025-07-30 |
详情>>
股本变动：
变动后总股本6278.44万股
|
| 2025-07-30 |
详情>>
业绩披露：
2025年中报每股收益-1.8美元,归母净利润-1.12亿美元,同比去年增长47.07%
|
| 2025-04-29 |
详情>>
业绩披露：
2025年一季报每股收益-1.01美元,归母净利润-6221.4万美元,同比去年增长42.65%
|
| 2025-04-29 |
财报披露：
美东时间 2025-04-29 盘后发布财报
|
| 2025-04-24 |
股东大会：
将于2025-06-11召开股东大会
会议内容 ▼▲
- 1.To elect two directors, James M. Frates and George Golumbeski, Ph.D., each to serve as a Class II director until the 2028 annual meeting of stockholders and until his successor is duly elected and qualified, subject to his earlier death, resignation, or removal;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.To hold a non-binding advisory vote to approve the compensation paid to our named executive officers;
4.To approve an amendment to the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan, as amended, or the 2014 ESPP, to increase the number of shares of our common stock authorized for issuance under the 2014 ESPP by 500,000 shares;
5.To transact such other business as may properly come before the meeting or any and all adjournments or postponements thereof.
|
| 2025-02-11 |
详情>>
业绩披露：
2024年年报每股收益-6.59美元,归母净利润-4.01亿美元,同比去年增长26.01%
|
| 2025-02-11 |
详情>>
业绩披露：
2022年年报每股收益-8.98美元,归母净利润-5.33亿美元,同比去年增长-16.36%
|
| 2024-10-29 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-5.03美元,归母净利润-3.05亿美元,同比去年增长40.08%
|
| 2024-07-31 |
详情>>
业绩披露：
2024年中报每股收益-3.5美元,归母净利润-2.11亿美元,同比去年增长31.19%
|
| 2024-04-25 |
详情>>
业绩披露：
2024年一季报每股收益-1.8美元,归母净利润-1.08亿美元,同比去年增长26.12%
|
| 2024-04-25 |
详情>>
业绩披露：
2023年一季报每股收益-2.46美元,归母净利润-1.47亿美元,同比去年增长-20.3%
|
| 2024-04-24 |
股东大会：
将于2024-06-10召开股东大会
会议内容 ▼▲
- 1.To elect two directors, Elizabeth Barrett and Geno Germano, each to serve as a Class I director until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified, subject to his or her earlier death, resignation, or removal.
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
3.To hold a non-binding advisory vote to approve the compensation paid to our named executive officers.
4.To approve the Sage Therapeutics, Inc. 2024 Equity Incentive Plan, or the 2024 Plan.
5.To transact such other business as may properly come before the meeting or any and all adjournments or postponements thereof.
|
| 2024-02-14 |
详情>>
业绩披露：
2023年年报每股收益-9.05美元,归母净利润-5.41亿美元,同比去年增长-1.63%
|
| 2023-12-19 |
股东大会：
将于2024-01-31召开股东大会
会议内容 ▼▲
- 1.To approve a one-time stock option exchange program for non-executive officer employees of Sage (the “Option Exchange Proposal”);
2.To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Option Exchange Proposal (the “Adjournment Proposal”).
|
| 2023-11-07 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-8.51美元,归母净利润-5.09亿美元,同比去年增长-31.93%
|
| 2023-08-07 |
详情>>
业绩披露：
2023年中报每股收益-5.14美元,归母净利润-3.07亿美元,同比去年增长-23.69%
|
| 2023-04-27 |
股东大会：
将于2023-06-15召开股东大会
会议内容 ▼▲
- 1.To elect four directors, Michael F. Cola, Barry E. Greene, Jeffrey M. Jonas, M.D., and Jessica J. Federer, each to serve as a Class III director until the 2026 annual meeting of stockholders and until his or her successor is duly elected and qualified, subject to his or her earlier death, resignation, or removal;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To hold a non-binding advisory vote to approve the compensation paid to our named executive officers;
4.To approve an amendment to our 2014 Employee Stock Purchase Plan, as amended, or the 2014 ESPP, to increase the number of shares of our common stock authorized for issuance under the 2014 ESPP by 500,000 shares;
5.To transact such other business as may properly come before the meeting or any and all adjournments or postponements thereof.
|
| 2022-04-28 |
股东大会：
将于2022-06-16召开股东大会
会议内容 ▼▲
- 1.to elect three directors, James M. Frates, George Golumbeski, Ph.D., and Kevin P. Starr, each to serve as a Class II director until the 2025 annual meeting of stockholders and until his successor is duly elected and qualified, subject to his earlier death, resignation, or removal;
2.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.to hold a non-binding advisory vote to approve the compensation paid to our named executive officers;
4.to hold a non-binding advisory vote to determine the frequency of future stockholder advisory votes on the compensation paid to our named executive officers;
5.to approve an amendment to our 2014 Employee Stock Purchase Plan, as amended, or the 2014 ESPP, to increase the number of shares of our common stock authorized for issuance under the 2014 ESPP by 300,000 shares;
6.to transact such other business as may properly come before the meeting or any and all adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-29 |
股东大会：
将于2021-06-10召开股东大会
会议内容 ▼▲
- 1.to elect three directors, Elizabeth Barrett, Geno Germano, and Steven Paul, M.D., each to serve as a Class I director until the 2024 annual meeting of stockholders and until his or her successor is duly elected and qualified, subject to his or her earlier death, resignation, or removal;
2.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.to hold a non-binding advisory vote to approve the compensation paid to our named executive officers;
4.to transact such other business as may properly come before the meeting or any and all adjournments or postponements thereof.
|
| 2020-04-29 |
股东大会：
将于2020-06-09召开股东大会
会议内容 ▼▲
- 1.to elect two directors, Michael F. Cola and Jeffrey M. Jonas, M.D., to serve as Class III directors until the 2023 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation, or removal;
2.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.to hold a non-binding advisory vote to approve the compensation paid to our named executive officers;
4.to transact such other business as may properly come before the meeting or any and all adjournments or postponements thereof.
|
| 2019-04-25 |
股东大会：
将于2019-06-05召开股东大会
会议内容 ▼▲
- 1.to elect three directors, Kevin P. Starr, James M. Frates and George Golumbeski, Ph.D., to serve as Class II directors until the 2022 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation, or removal;
2.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.to hold a nonbinding advisory vote to approve the compensation paid to our named executive officers;
4.to transact such other business as may properly come before the meeting or at any and all adjournments or postponements thereof.
|
| 2018-04-30 |
股东大会：
将于2018-06-06召开股东大会
会议内容 ▼▲
- 1.to elect two directors, Geno Germano and Steven Paul, to serve as Class I directors until the 2021 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation, or removal;
2.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.to hold a nonbinding advisory vote to approve the compensation paid to our named executive officers;
4.to transact such other business as may properly come before the meeting or at any and all adjournments or postponements thereof.
|
| 2017-04-28 |
股东大会：
将于2017-06-07召开股东大会
会议内容 ▼▲
- 1. to elect two directors, Michael Cola and Jeffrey M. Jonas, to serve as Class III directors until the 2020 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation, or removal;
2. to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
3. to hold a nonbinding advisory vote to approve the compensation paid to our named executive officers;
4. to transact such other business as may properly come before the meeting or at any and all adjournments or postponements thereof.
|
| 2016-04-29 |
股东大会：
将于2016-06-22召开股东大会
会议内容 ▼▲
- 1. to elect two directors, Kevin P. Starr and James Frates, to serve as Class II directors until the 2019 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal;
2. to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
3. to hold an advisory vote to determine the frequency of future stockholder advisory votes on the compensation paid to our named executive officers;
4. to transact such other business as may properly come before the meeting or at any and all adjournments or postponements thereof.
|